![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, May 02, 2011 10:10:27 AM
--------------------------------------------------------------------------------
21-
Changes in Registrant's Certifying Accountant, Financial Statement
Item 4.01 Changes in Registrant's Certifying Accountant.
Effective April 19, 2011, Ernst & Young LLP (UK) ("E&Y UK") resigned as the independent registered public accounting firm that audits the financial statements of Cyclacel Pharmaceuticals, Inc. (the "Company"), which resignation was accepted by the Company's Board of Directors (the "Board") as of the same date.
At the recommendation of the Audit Committee of the Board, effective April 19, 2011, the Board engaged Ernst & Young LLP (US) ("E&Y US"), as the independent registered public accounting firm to audit the Company's financial statements for the year ended December 31, 2011, such engagement to be ratified by the Company's stockholders at the Company's annual meeting of stockholders. E&Y UK's audit reports on the Company's financial statements for the years ended December 31, 2010 and 2009 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles.
During the Company's two most recent fiscal years and any subsequent interim period prior to the date of this Report, there were no disagreements with E&Y UK on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of E&Y UK, would have caused it to make reference to the subject matter thereof in connection with its report.
During the Company's two most recent fiscal years and any subsequent interim period prior to the date of this Report, none of the events described in paragraphs (A) through (D) of Item 304(a)(1)(v) of Regulation S-K under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), occurred, except that, as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and the Annual Report on Form 10-K/A for the year ended December 31, 2009, E&Y UK advised the Company that it did not have an effectively-designed control in operation over the accounting for, presentation of and disclosure of cumulative preferred stock dividends to prevent or detect on a timely basis material misstatements in the computation of net loss per share and the financial statement presentation of preferred stock dividends. During the Company's two most recent fiscal years and any subsequent interim period prior to the date of this Report, neither the Company nor anyone acting on its behalf consulted E&Y US regarding (a) the application of accounting principles to a specified transaction, either completed or proposed or the type of audit opinion that might be rendered on the Company's financial statements or
(b) any (i) matter that was the subject of a disagreement with E&Y UK on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of E&Y UK, would have caused it to make reference to the subject matter thereof in connection with its report or (ii) events described in paragraphs (A) through (D) of Item 304(a)(1)(v) of Regulation S-K under the Exchange Act. The Company has provided E&Y UK with a copy of this Report prior to the filing hereof and has requested that E&Y UK furnish to the Company a letter addressed to the Securities and Exchange Commission stating whether E&Y UK agrees with the statements made by the Company in this Report. E&Y UK has furnished such letter, which letter is filed as Exhibit 99.1 hereto, as required by Item 304(a)(3) of Regulation S-K.
Recent CYCC News
- Cyclacel Announces Notice of Intention to Grant New European Patent Covering Plogosertib Pharmaceutical Compositions • GlobeNewswire Inc. • 06/26/2024 01:15:00 PM
- Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 06/04/2024 12:00:00 PM
- Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/14/2024 08:05:00 PM
- Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 01:15:00 PM
- Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules • GlobeNewswire Inc. • 05/02/2024 08:30:00 PM
- $8 Million Private Placement Announcement Sends Biotech Flying • AllPennyStocks.com • 04/30/2024 05:51:00 PM
- Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer • GlobeNewswire Inc. • 04/01/2024 01:15:00 PM
- Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/19/2024 08:05:00 PM
- US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat • IH Market News • 03/19/2024 11:27:29 AM
- Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/13/2024 08:05:00 PM
- Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/07/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit • GlobeNewswire Inc. • 03/06/2024 02:15:00 PM
- Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/20/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer • GlobeNewswire Inc. • 01/30/2024 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions • GlobeNewswire Inc. • 12/18/2023 02:00:00 PM
- Cyclacel Pharmaceuticals Announces Reverse Stock Split • GlobeNewswire Inc. • 12/12/2023 09:05:00 PM
- Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC • GlobeNewswire Inc. • 11/30/2023 02:15:00 PM
- Cyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/28/2023 10:15:00 PM
- Cyclacel Pharmaceuticals to Release Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/07/2023 02:15:00 PM
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/09/2023 08:05:00 PM
- Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/03/2023 01:15:00 PM
FEATURED POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM
Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM
Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM
Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM